Clinical Trials Directory

Trials / Completed

CompletedNCT00864981

A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Sandoz · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGBupropion HCI ER Tablets, 150 mg; EON Labs Inc.
DRUGWELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline

Timeline

Start date
2005-09-01
Primary completion
2005-10-01
Completion
2005-10-01
First posted
2009-03-19
Last updated
2017-03-29

Source: ClinicalTrials.gov record NCT00864981. Inclusion in this directory is not an endorsement.